secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K/A
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001641172-25-002602
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan
----------------------------------------------------------------------------

- Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.
- NDPD held patents for PLM (PHGG) to treat COVID-19 and 60+ viruses; appraised asset value $15.85M including license.
- Related-party accounting (ASC 805-50) requires purchase price of $12.47M to be eliminated against equity, not recorded as assets.
- CFO Ola Soderquist adopted a 10b5-1 plan to sell up to 500,000 shares by Dec 31, 2025, contingent on price thresholds.
- NDPD was beneficially owned by company officers; transaction approved by board as a related-party acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000164117225002602/0001641172-25-002602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000164117225002602/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-002602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer